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a b s t r a c t
Background and objective: Management of outpatients with stable coronary artery disease
(CAD) is important in secondary prevention. The objective was to describe differences in the
characteristics of CAD patients in Latvia compared with other countries.
Materials and methods: CLARIFY is an ongoing international, prospective, observational,
longitudinal registry of outpatients with CAD. Data regarding treated outpatients with
established CAD from the CLARIFY registry in Latvia (n = 120) were compared with those
from the rest of Central-Eastern Europe (CEE) (n = 2888) and worldwide (n = 33,163).
Results: Patients in Latvia had a larger waist circumference (101 [95–109] vs. 99 [91–106] in
CEE, 96.5 [88–105] cm worldwide; P = 0.023 and P < 0.001, respectively) and higher blood
pressure (systolic: 138.28  17.13 vs. 133.77  16.47 in CEE and 130.97  16.65 mm Hg world-
wide, P = 0.003 and P < 0.001; diastolic: 82.98  8.58 vs. 80.01  9.61 in CEE and 77.22
 9.97 mm Hg worldwide, P < 0.001 and P < 0.001, respectively). Body mass index in Latvia
did not differ signiﬁcantly from that in CEE (P = 0.422), but was higher than worldwide (28.8
[26.2–32.0] vs. worldwide 27.3 [24.8–30.3] kg/m2, P < 0.001). The history of percutaneous
coronary intervention was more frequent in Latvia (74.17% vs. 59.34% in CEE and 58.61%
worldwide, P = 0.001 and P < 0.001, respectively). Latvian patients more frequently used
Peer review under the responsibility of the Lithuanian University of Health Sciences.
* Corresponding author at: Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Pilsonu 13, 1002 Riga, Latvia.
E-mail address: a.a.erglis@stradini.lv (A. Erglis).
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: http://www.elsevier.com/locate/medicihttp://dx.doi.org/10.1016/j.medici.2015.05.004
1010-660X/# 2015 Lithuanian University of Health Sciences. Production and hosting by Elsevier Sp. z o.o. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
aspirin (97.50% in Latvia vs. 89.75% in CEE and 87.64% worldwide, P = 0.005 and P = 0.001,
respectively).
Conclusions: Latvian CAD patients are well managed in terms of aspirin use and frequency of
percutaneous coronary intervention. Control of obesity and high BP is poorer and needs
further improvement.
# 2015 Lithuanian University of Health Sciences. Production and hosting by Elsevier
Sp. z o.o. This is an open access article under the CC BY-NC-ND license (http://creative-
commons.org/licenses/by-nc-nd/4.0/).
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Coronary artery disease (CAD) is a highly prevalent cardio-
vascular (CV) disease and the main cause of mortality
worldwide [1]. In terms of CV diseases the epidemiological
situation is on average less favorable in Latvia than in the
European Union [2]. Population aging and improved prognosis
of coronary patients may increase the number of CAD
patients in the future [3]. Despite the presence of country-
and region-speciﬁc differences in the characteristics and
management of CAD patients, there is a lack of data regarding
the situation in Latvia vs the rest of Central-Eastern Europe
and worldwide data. The prospeCtive observationaL Longi-
tudinAl RegIstry oF patients with stable coronary arterY
disease (CLARIFY) registry was initiated to gather additional
knowledge regarding outpatients with stable CAD: to describe
the population of treated outpatients with stable CAD
(demographics, risk factors, management, outcomes), to
identify discrepancies between evidence-based recommen-
dations and routine treatment in practice, and to identify
long-term prognostic determinants in CAD outpatients [4]. A
better understanding of the situation of risk factor control and
the management and treatment of CAD patients in Latvia,
taking into account the position of Latvia among other
countries, would help to deﬁne the areas requiring further
improvement for successful secondary prevention. The
objective of the study was to describe geographical and
international differences in the characteristics of treated
stable CAD patient populations by comparison of data from
CLARIFY Latvia and CLARIFY Central-Eastern Europe, and
from worldwide populations.
2. Materials and methods
The CLARIFY is an ongoing international, prospective, obser-
vational, longitudinal registry of outpatients with established
CAD, in which patients are followed up for 5 years. A total of
33,283 patients from 45 countries worldwide were included in
the registry [5]. The rationale of the registry, its methods, and
its worldwide baseline data have been published previously
[4,5]. Patients were eligible for enrollment if at least one of the
inclusion criteria was present: documented myocardial in-
farction (more than 3 months ago), coronary stenosis of more
than 50% on coronary angiography, chest pain in combination
with myocardial ischemia (conﬁrmed by stress electrocardio-
gram [ECG], stress echocardiography or myocardial imaging),coronary revascularization (coronary artery bypass graft or
percutaneous coronary intervention [PCI]) at least 3 months
ago. Exclusion criteria were hospitalization due to CV disease
within the last 3 months, planned revascularization, and
conditions expected to interfere with participation or 5-year
follow-up.
In Latvia, 120 patients were included in the CLARIFY
registry during 2009–2010. Patients were managed by physi-
cians according to usual clinical practice at each institution
with no speciﬁc tests or treatment changes deﬁned in the
protocol. Approval was obtained from the Ethics Committee of
the Research Institute of Cardiology, University of Latvia,
before enrollment of patients in the registry in Latvia.
During a baseline visit, the following data were collected:
demographic information, medical history, risk factors and
lifestyle, physical examination data, heart rate (measured by
both pulse palpation and ECG), current symptoms, most recent
laboratory values, as well as information about current
medical treatment. Heart rate by pulse palpation was
measured for 30 s after sitting for at least 5 min in a quiet
room at comfortable temperature. Of two different measure-
ments, the second was recorded. Blood pressure was mea-
sured in sitting position after being at rest at least 5 min. The
most recent (within 6 months) 12-lead ECG was analyzed. For
assessment of heart failure symptoms, the New York Heart
Association (NYHA) classiﬁcation was used. Laboratory values
were collected if data were available. Data were collected by
using standardized, international case report forms translated
into the local language. Completed electronic case report
forms using these data were sent to the data management
center in Glasgow.
In order to understand between-country differences in the
characteristics and management of patients with stable CAD,
CLARIFY Latvia data from baseline visit were compared with
the data from other Central-Eastern Europe countries, as well
with global data. The total number of patients enrolled in
CLARIFY in Central-Eastern Europe was 3008. Latvia was
compared with the rest of Central-Eastern Europe (n = 2888)
(Bulgaria, Czech Republic, Hungary, Lithuania, Poland, Roma-
nia, Slovakia, Slovenia), as well as with the other countries
involved (n = 33,163). Apart from Central-Eastern Europe,
global data included information also from Western Europe
(Belgium, Denmark, France, Germany, Greece), North America
(Canada), Central America (Mexico), West Indies, South
America (Argentina, Brazil), Africa, Middle East (Bahrain,
Kuwait, Oman, Qatar, UAE, and Saudi Arabia), Russia, Ukraine,
Asia (Brunei, China, India, Korea, Malaysia, Singapore,
Thailand, Vietnam), and Australasia (Australia).
Table 1 – Baseline characteristics of the study population classified according to Latvia vs rest of Central-Eastern Europe and Latvia vs rest of world.
Parameter Total Central-
Eastern Europe
(n = 3008)
Total worldwide
(n = 33,283)
Population P (Latvia vs other
Central-Eastern
European countries)
P (Latvia vs
rest of world)
Latvia
(n = 120)
Other Central-
Eastern European
countries (n = 2888)
Rest of world
(n = 33,163)
Age, years mean  SD 62.43  9.43 64.15  10.48 64.19  7.95 62.35  9.48 64.15  10.49 0.037* 0.966
Men, n (%) 2196 (73.20) 25,761 (77.49) 87 (72.50) 2109 (73.23) 25,674 (77.50) 0.860 0.190
Body mass index, kg/m2, median (Q1–Q3) 28.6 (26.1–31.5) 27.3 (24.8–30.3) 28.8 (26.2–32.0) 28.6 (26.1–31.4) 27.3 (24.8–30.3) 0.422 <0.001***
Waist circumference, cm, median (Q1–Q3) 99.0 (91.0–106.0) 96.5 (88.0–105.0) 101.0 (95.0–109.0) 99.0 (91.0–106.0) 96.5 (88.0–105.0) 0.023* <0.001***
Medical history, n (%)
Myocardial infarction 2011 (67.03) 19,849 (59.70) 76 (63.33) 1935 (67.19) 19,773 (59.69) 0.379 0.416
PCI 1798 (59.93) 19,506 (58.67) 89 (74.17) 1709 (59.34) 19,417 (58.61) 0.001** <0.001***
CABG 818 (27.28) 7784 (23.41) 29 (24.17) 789 (27.41) 7755 (23.41) 0.435 0.845
ICD 41 (1.37) 414 (1.25) 0 (0.00) 41 (1.42) 414 (1.25) 0.410 0.410
Pacemaker 76 (2.53) 796 (2.39) 3 (2.50) 73 (2.53) 793 (2.39) 1.000 0.765
Hospitalization for CHF 178 (5.93) 1552 (4.67) 2 (1.67) 176 (6.11) 1550 (4.68) 0.044* 0.119
Stroke 152 (5.07) 1327 (3.99) 3 (2.50) 149 (5.17) 1324 (4.00) 0.191 0.636
Atrial ﬁbrillation/ﬂutter 239 (7.97) 2328 (7.00) 12 (10.00) 227 (7.88) 2316 (6.99) 0.401 0.197
Asthma/COPD 193 (6.44) 2453 (7.38) 7 (5.83) 186 (6.46) 2446 (7.38) 0.784 0.517
Risk factors and lifestyle, n (%)
Family history of premature CADa 991 (33.07) 9461 (28.46) 29 (24.17) 962 (33.44) 9432 (28.48) 0.034* 0.296
Treated hypertension 2458 (81.93) 23,591 (70.96) 94 (78.33) 2364 (82.08) 23,497 (70.93) 0.296 0.075
Diabetes 844 (28.13) 9696 (29.16) 25 (20.83) 819 (28.44) 9671 (29.19) 0.070 0.044*
Dyslipidemia 2651 (88.37) 24,889 (74.86) 113 (94.17) 2538 (88.13) 24,776 (74.79) 0.043* <0.001***
PAD 306 (10.21) 3255 (9.79) 8 (6.67) 298 (10.35) 3247 (9.80) 0.191 0.249
Smoking status, n (%)
Current 367 (12.25) 4126 (12.41) 21 (17.50) 346 (12.03) 4105 (12.39) 0.054 0.215
Former 1516 (50.60) 15,093 (45.40) 49 (40.83) 1467 (51.01) 15,044 (45.41)
Never 1113 (37.15) 14,029 (42.20) 50 (41.67) 1063 (36.96) 13,979 (42.20)
Alcohol intake, drinks per week, n (%)
0 1134 (37.83) 16,082 (48.38) 38 (31.67) 1096 (38.08) 16,044 (48.44) 0.233 <0.001***
>0 and <20 1805 (60.21) 15,977 (48.06) 78 (65.00) 1727 (60.01) 15,899 (48.00)
20+ 59 (1.97) 1184 (3.56) 4 (3.33) 55 (1.91) 1180 (3.56)
Stimulant drinks consumed, n (%)
Coffee 1740 (58.10) 15,657 (47.14) 71 (59.17) 1669 (58.05) 15,586 (47.09) <0.001*** <0.001***
Tea 891 (29.75) 10,186 (30.67) 47 (39.17) 844 (29.36) 10,139 (30.64)
Neither 364 (12.15) 7373 (22.20) 2 (1.67) 362 (12.59) 7371 (22.27)
Daily intake of stimulant drinks
(cups per day), median (Q1–Q3)
2 (1–3) 2 (2–4) 2 (1–3) 2 (1–3) 2 (2–4) 0.042* <0.001***
Physical activity
None 275 (9.17) 5419 (16.30) 8 (6.67) 267 (9.27) 5411 (16.34) 0.024* <0.001***
Lightb 1555 (51.83) 17,057 (51.31) 55 (45.83) 1500 (52.08) 17,002 (51.33)
1–2 times per weekc 591 (19.70) 5578 (16.78) 21 (17.50) 570 (19.79) 5557 (16.78)
≥3 times per weekc 579 (19.30) 5187 (15.60) 36 (30.00) 543 (18.85) 5151 (15.55)
Current symptoms, n (%)
Angina 979 (32.63) 7315 (22.00) 57 (47.50) 922 (32.01) 7258 (21.91) <0.001*** <0.001***
CHF symptoms
None 2365 (78.83) 28,298 (85.13) 51 (42.50) 2314 (80.35) 28,247 (85.28) <0.001*** <0.001***
NYHA II 529 (17.63) 4135 (12.44) 62 (51.67) 467 (16.22) 4073 (12.30)
NYHA III 106 (3.53) 808 (2.43) 7 (5.83) 99 (3.44) 801 (2.42)
Creatinine, mmol/L, median (Q1–Q3) 0.087 (0.075–0.100) 0.088 (0.076–0.102) 0.085 (0.073–0.100) 0.087 (0.075–0.100) 0.088 (0.076–0.102) 0.752 0.392
Blood glucose, mmol/L, median (Q1–Q3) 5.7 (5.2–6.6) 5.7 (5.1–6.6) 5.7 (5.2–6.4) 5.7 (5.2–6.6) 5.7 (5.1–6.6) 0.950 0.857
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Total cholesterol, mmol/L, median (Q1–Q3) 4.6 (3.9–5.4) 4.3 (3.7–5.0) 4.5 (3.9–5.1) 4.6 (3.9–5.4) 4.3 (3.7–5.0) 0.3190 0.0520
HDL-C, mmol/L, median (Q1–Q3) 1.19 (1.00–1.41) 1.14 (0.96–1.37) 1.21 (1.01–1.56) 1.19 (1.00–1.40) 1.14 (0.96–1.37) 0.155 0.008**
LDL-C, mmol/L, median (Q1–Q3) 2.60 (2.03–3.30) 2.37 (1.90–2.94) 2.58 (1.97–3.09) 2.60 (2.03–3.30) 2.37 (1.90–2.94) 0.419 0.060
Triglycerides, mmol/L, median (Q1–Q3) 1.5 (1.1–2.1) 1.4 (1.0–1.9) 1.4 (1.0–2.0) 1.5 (1.1–2.1) 1.4 (1.0–1.9) 0.204 0.880
Heart rate (palpation), bpm, mean  SD 69.14  10.02 68.29  10.62 67.96  9.65 69.19  10.03 68.29  10.62) 0.188 0.733
ECG heart rate, bpm, mean  SD 68.25  11.05 67.18  11.44 67.17  10.88 68.30  11.05 67.18  11.45 0.274 0.993
SBP (mm Hg), mean  SD 133.95  16.52 131.00  16.66 138.28  17.13 133.77  16.47 130.97  16.65 0.003** <0.001***
DBP (mm Hg), mean  SD 80.13  9.58 77.24  9.97 82.98  8.58 80.01  9.61 77.22  9.97 <0.001*** <0.001***
LVEF (%), mean  SD 53.15  9.75 56.11  11.09 57.07  8.70 52.99  9.76 56.10  11.10 <0.001*** 0.392
Presence of coronary stenosis >50%, n (%)
Left main stenosisd 161 (5.35) 2865 (8.61) 13 (10.83) 148 (5.12) 2852 (8.60) 0.007** 0.384
LAD stenosisd 1739 (57.81) 19,321 (58.05) 83 (69.17) 1656 (57.34) 19,238 (58.01) 0.010* 0.013*
Cx stenosisd 1118 (37.17) 11,924 (35.83) 56 (46.67) 1062 (36.77) 11,868 (35.79) 0.028* 0.013*
RCA stenosisd 1347 (44.78) 14,368 (43.17) 73 (60.83) 1274 (44.11) 14,295 (43.11) <0.001*** <0.001***
CABG stenosisd 249 (8.28) 2657 (7.98) 19 (15.83) 230 (7.96) 2638 (7.95) 0.002** 0.002**
No stenosis 93 (3.09) 1070 (3.21) 1 (0.83) 92 (3.19) 1069 (3.22) 0.182 0.191
Coronary angiography not done 442 (14.69) 4867 (14.62) 7 (5.83) 435 (15.06) 4860 (14.65) 0.005** 0.006**
Test for myocardial ischemiae, n (%) 2018 (67.29) 20,581 (61.93) 108 (90.00) 1910 (66.34) 20,473 (61.83) <0.001*** <0.001***
Current evidence of ischemia, n (%) 635 (21.17) 5369 (16.16) 8 (6.67) 627 (21.78) 5361 (16.19) <0.001*** 0.005**
ECG rhythm, n (%)
Sinus rhythm 2539 (95.13) 23,382 (94.94) 113 (94.96) 2426 (95.14) 23,269 (94.94) 0.940 0.945
Atrial ﬁbrillation/ﬂutter 77 (2.88) 841 (3.41) 4 (3.36) 73 (2.86) 837 (3.42)
Paced rhythm 53 (1.99) 404 (1.64) 2 (1.68) 51 (2.00) 402 (1.64)
n, number of patients; Y, years; SD, standard deviation; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; ICD, internal cardiac deﬁbrillator; CHF, chronic heart failure; COPD, chronic obstructive pulmonary
disease; CAD, coronary artery disease; PAD, peripheral arterial disease; NYHA, New York Heart Association; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; bpm, beats per minute; ECG,
electrocardiogram; SBP, systolic blood pressure; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; LAD, left anterior descending; Cx, circumﬂex; RCA, right coronary artery.
a Myocardial infarction, sudden death, stable angina at age <55 years (men) or 65 years (women) in a ﬁrst-degree relative.
b Light physical activity most weeks.
c At least 20 min vigorous physical activity.
d Coronary territories with stenosis >50% at coronary angiography or having required revascularization in the past.
e Noninvasive test for myocardial ischemia (stress ECG, stress echocardiography, myocardial imaging).
* P < 0.05.
** P < 0.01.
*** P < 0.001.
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m e d i c i n a 5 1 ( 2 0 1 5 ) 2 4 0 – 2 4 6244All CLARIFY data are stored and analyzed at the Robertson
Centre for Biostatistics, University of Glasgow, UK. Continuous
data are summarized using mean and standard deviation (SD),
or median and interquartile range (IQR) depending on the
distribution of data. Categorical data are summarized using
counts and percentages. Summaries are provided for CLARIFY
Latvia, Central-Eastern Europe, as well as global data. In order
to analyze clinical characteristics and medications according
to population (Latvia vs rest of Central-Eastern Europe or
Latvia vs rest of global data), P values for between-group
differences were calculated using either the chi-square or
Fisher exact tests for categorical variables, depending on the
data, and for continuous variables using either one-way
analysis of variance or the Kruskal–Wallis test, depending
on the distribution of the data. Statistical analyses were
performed using Statistical Analysis Software (version 9.2). A
signiﬁcance level of 0.05 was used to test for statistical
differences throughout and all tests used were two-sided.
Height and weight were used to calculate body mass index
in kg/m2.
3. Results
The characteristics of the CLARIFY population in Latvia in
comparison with the population of the rest of Central-Eastern
Europe and the rest of world population are summarized in
Table 1. CLARIFY patients in Latvia were signiﬁcantly older
than in the rest of Central-Eastern Europe and with a higher
body mass index than the rest of the CLARIFY worldwide
population (Table 1). Mean waist circumference of patients
was larger in Latvia. Latvian patients more frequently had a
history of PCI than patients in the rest of Central-Eastern
Europe or worldwide (Table 1). Signiﬁcantly fewer patients
were hospitalized due to heart failure in Latvia vs the rest of
Central-Eastern Europe (Table 1). CLARIFY patients in Latvia
less frequently had a family history of premature CAD in
comparison with the rest of Central-Eastern Europe and less
frequently had diabetes in comparison with the rest of
worldwide population, whereas a larger proportion of patients
had dyslipidemia in Latvia than in the rest of Central-Eastern
Europe or in the worldwide population (Table 1). Alcohol
intake was higher in Latvia than worldwide (the higher
moderate alcohol intake of between 0 and 20 drinks per week
rather than +20 drinks per week). Patients used more
stimulant drinks (tea, coffee) and were more physically active
in Latvia than in the rest of Central-Eastern Europe and
worldwide (Table 1). When analyzing current symptoms,
angina, as well as symptoms of heart failure, was more
frequent in the Latvian population than in the rest of Central-
Eastern Europe or worldwide (Table 1). The level of high-
density lipoprotein cholesterol was higher in Latvian patients
vs the CLARIFY population worldwide (Table 1). Mean heart
rate did not differ signiﬁcantly, but systolic blood pressure and
diastolic blood pressure were higher in Latvia vs other Central-
Eastern European countries and worldwide (Table 1). Left
ventricular ejection fraction was greater in Latvia than in other
Central-Eastern European countries (Table 1). In Latvia there
were fewer people in whom coronary angiography was not
done. Coronary stenosis >50% was more frequent in Latviathan in the rest of Central-Eastern Europe or worldwide (the
exception was left main stenosis which differed from other
Central-Eastern European countries but not from other
countries worldwide) (Table 1). Tests for myocardial ischemia
was more frequently done in the Latvian population, but there
were signiﬁcantly fewer patients with current evidence of
ischemia than in the rest of Central-Eastern Europe or in the
CLARIFY population worldwide (Table 1).
Medications taken by the Latvian patients vs. the rest of
Central-Eastern Europe and worldwide are summarized in
Table 2. CLARIFY patients in Latvia were more frequently on
aspirin, calcium antagonists (dihydropyridines) and antiar-
rhythmics, but less frequently on other antiplatelet drugs. A
larger proportion of Latvian patients had symptoms indicative
of intolerance or contraindication to beta-blockers when
compared with the rest of Central-Eastern Europe and
worldwide (Table 2). A signiﬁcantly smaller proportion of
Latvian patients were using beta-blockers, oral anticoagulants,
verapamil or diltiazem, other antianginal agents, and diuretics
than in the rest of Central-Eastern Europe (Table 2). When
comparing Latvian data with the CLARIFY worldwide data,
angiotensin-converting enzyme inhibitors or angiotensin II
receptor blockers were more frequently used in Latvia, while
the proportion of patients on thienopyridine was higher in the
rest of worldwide population (Table 2).
4. Discussion
Comparison of the Latvian CLARIFY population with CLARIFY
patients from the rest of Central-Eastern Europe and world-
wide shows several directions for further improvement of
secondary prevention in CAD patients in Latvia, and highlights
areas where Latvian physicians are successful.
A population-based cross-sectional study of cardiovascular
risk factors in Latvia showed that dyslipidemia is the most
frequent cardiovascular risk factor in the general population as
it was present in 75.2% of analyzed adult responders (n = 3807)
and in 81.9% of men in the age group 65–74 years (n = 929) [6].
High prevalence of dyslipidemia in the Latvian general
population may explain why this risk factor is frequently
found among CAD patients. In the Latvian CLARIFY sample the
prevalence of dyslipidemia is signiﬁcantly higher than in other
Central-Eastern Europe countries or worldwide. However, it
may be that Latvian physicians more frequently recognize
dyslipidemia as a risk factor, because the levels of total
cholesterol and low-density lipoprotein cholesterol did not
differ signiﬁcantly. The level of high-density lipoprotein
cholesterol in the CLARIFY Latvia population is higher than
in the worldwide population and could be linked to a higher
level of physical activity in Latvian patients. Use of lipid-
lowering agents is high in the Latvian CLARIFY population and
in the rest of Central-Eastern Europe and worldwide. At the
beginning of the 21st century use of statins in CAD patients
was extremely low. In a study in Latvia in 2002, only 29% of 403
CAD patients analyzed were using lipid-lowering drugs [7].
That 95% of Latvian CLARIFY patients are now treated with
lipid-lowering drugs is a great achievement.
Our analysis shows not only a good proportion of patients
taking lipid-lowering agents, but also good frequency of use of
Table 2 – Medications of the study population classified according to Latvia vs rest of Central-Eastern Europe and Latvia vs rest of world.
Parameter Total Central-
Eastern Europe
(n = 3008)
Total worldwide
(33,283)
Population P (Latvia vs other
Central-Eastern
European countries)
P (Latvia vs
rest of world)
Latvia
(n = 120)
Other Central-
Eastern European
countries (n = 2888)
Rest of world
(33,163)
Aspirin, n (%) 2700 (90.06) 29,144 (87.68) 117 (97.50) 2583 (89.75) 29,027 (87.64) 0.005** 0.001**
Thienopyridine, n (%) 612 (20.43) 9036 (27.22) 18 (15.00) 594 (20.65) 9018 (27.26) 0.132 0.003**
Other antiplatelet drugs, n (%) 207 (6.91) 3084 (9.29) 1 (0.83) 206 (7.16) 3083 (9.32) 0.007** 0.001**
Oral anticoagulants, n (%) 287 (9.57) 2737 (8.24) 4 (3.33) 283 (9.83) 2733 (8.26) 0.018* 0.050
Beta-blockers, n (%) 2670 (89.03) 24,984 (75.16) 98 (81.67) 2572 (89.34) 24,886 (75.13) 0.008** 0.098
Symptoms indicative of
intolerance or contraindication
to beta-blockers, n (%)
435 (14.50) 4797 (14.43) 25 (20.83) 410 (14.24) 4772 (14.41) 0.045* 0.046*
Ivabradine, n (%) 275 (9.17) 3268 (9.83) 14 (11.67) 261 (9.07) 3254 (9.82) 0.334 0.499
Calcium antagonists, n (%) 863 (28.79) 9059 (27.25) 65 (54.17) 798 (27.73) 8994 (27.16) <0.001*** <0.001***
Verapamil or diltiazem 109 (3.64) 1933 (5.82) 0 (0.00) 109 (3.79) 1933 (5.84) 0.022* 0.006**
ACE inhibitors/angiotensin II
receptor blockers n (%)
2614 (87.19) 25,275 (76.04) 103 (85.83) 2511 (87.25) 25,172 (76.00) 0.650 0.012*
Lipid-lowering drugs, n (%) 2845 (94.86) 30,688 (92.31) 114 (95.00) 2731 (94.86) 30,574 (92.30) 0.946 0.269
Long-acting nitrates, n (%) 584 (19.48) 7359 (22.14) 28 (23.33) 556 (19.32) 7331 (22.13) 0.277 0.752
Other antianginal agents, n (%) 726 (24.22) 4639 (13.96) 15 (12.50) 711 (24.70) 4624 (13.96) 0.002** 0.644
Diuretics, n (%) 1174 (39.17) 9715 (29.23) 31 (25.83) 1143 (39.73) 9684 (29.24) 0.002** 0.412
Other antihypertensive agents, n (%) 275 (9.17) 2281 (6.86) 11 (9.17) 264 (9.17) 2270 (6.85) 0.998 0.317
Digoxin and derivatives, n (%) 87 (2.90) 838 (2.52) 3 (2.50) 84 (2.92) 835 (2.52) 1.000 1.000
Amiodarone/dronedarone, n (%) 95 (3.17) 972 (2.92) 5 (4.17) 90 (3.13) 967 (2.92) 0.430 0.405
Other antiarrythmics, n (%) 26 (0.87) 311 (0.94) 4 (3.33) 22 (0.76) 307 (0.93) 0.018* 0.027*
Antidiabetic agents, n (%) 640 (21.35) 8182 (24.61) 2 (19.17) 617 (21.44) 8159 (24.63) 0.552 0.165
n, number of patients; ACE, angiotensin-converting enzyme.
* P < 0.05.
** P < 0.01.
*** P < 0.001.
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m e d i c i n a 5 1 ( 2 0 1 5 ) 2 4 0 – 2 4 6246other preventive treatments. For example, the number of
CLARIFY patients on aspirin is higher in Latvia than in other
Central-Eastern European countries and worldwide, and the
usage of angiotensin-converting enzyme inhibitors is more
frequent than worldwide.
Current analysis also shows that CAD patients in Latvia are
well managed in some other regards. The proportion of
CLARIFY patients with PCI is signiﬁcantly high in Latvia,
although one cannot exclude selection bias. In spite of a
signiﬁcantly lower rate of ischemic symptoms among CLARIFY
Latvia patients, testing for ischemia was more frequent than in
other countries, showing that physicians are willing to
examine CAD patients on a regular basis.
However, there are areas for further improvement in the
management and treatment of CAD in Latvia. CLARIFY
patients in Latvia have a larger waist circumference and
higher body mass index despite higher levels of physical
activity than in other countries. This indicates a need for
improvement in eating habits and further increase in physical
exercise. Greater use of stimulant drinks (coffee and tea) and
alcohol in the CLARIFY Latvia population raises the question of
whether there is a need for further education of patients.
The mean blood pressure in CLARIFY Latvia patients is
higher than in other countries. Relatively low rate of treated
CAD with controlled blood pressure in Latvia (41.4%) was also
seen in EUROASPIRE III [8], and indicates a need to improve the
treatment of hypertension in Latvian CAD patients.
The current analysis gives an objective view of the level of
CAD management in Latvia, taking into account the global
context. Our study ﬁndings will help practitioners to further
improve the management of CAD outpatients in Latvia and
therefore to succeed in secondary prevention.
Limitations on data interpretation should be acknowledged
as the analyzed sample of CAD patients in Latvia is relatively
small. There may also have been selection bias. The surveyed
population may therefore not fully reﬂect the situation in the
total population of stable CAD patients in Latvia. For a better
understanding of the characteristics, management, and
treatment of CAD patients in Latvia, studies with a larger
number of patients are necessary.
5. Conclusions
Latvian CAD patients are well managed in several regards,
such as use of aspirin and frequency of PCI. Control of obesity
and high blood pressure is poorer in Latvia and needs further
improvement.
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